
|Articles|June 5, 2014
Research into MPDL3280A for the Treatment of Lung Cancer
Author(s)David Spigel, MD
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
Advertisement
David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, provides an update on research into MPDL3280A for the treatment of patients with lung cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
5








































